1,051 results on '"Herzog, Roland W."'
Search Results
2. AAV vectors tested in perfused human livers: Gene therapy
3. SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model
4. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
5. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
6. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
7. TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
8. Cellular stress and coagulation factor production: when more is not necessarily better
9. Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration
10. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
11. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
12. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
13. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
14. Plant cell-based drug delivery enhances affordability of biologics
15. Adding recombinant AAVs to the cancer therapeutics mix
16. Fast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS/MS
17. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma
18. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice
19. Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes
20. Immune complications and their management in inherited and acquired bleeding disorders
21. Assessment of the Gene Therapy Immune Response in the Canine Muscular Dystrophy Model
22. Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette
23. Role of orally induced regulatory T cells in immunotherapy and tolerance
24. Redundancy in Innate Immune Pathways That Promote CD8 + T-Cell Responses in AAV1 Muscle Gene Transfer.
25. Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity
26. Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice
27. A Molecular Revolution in the Treatment of Hemophilia
28. Immune Responses to Viral Gene Therapy Vectors
29. Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells
30. In memoriam: Kenneth I. Berns, MD, PhD (1938–2024)
31. Kenneth I. Berns, MD, PhD [1938–2024]
32. Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations
33. Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes
34. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
35. Complexity of immune responses to AAV transgene products – Example of factor IX
36. Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer
37. SLAMF6 in health and disease: Implications for therapeutic targeting
38. Viral Vector Based Immunotherapy for Peanut Allergy.
39. Innate Immune Sensing of Adeno-Associated Virus Vectors.
40. Update on clinical gene therapy for hemophilia
41. Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography
42. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
43. The Nobel Prize awarded to pioneers of mRNA vaccines
44. Looking to the future of gene therapy for hemophilia A and B
45. Cellular stress and coagulation factor production: when more isn’t necessarily better
46. Potential role for oral tolerance in gene therapy
47. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T Cells
48. Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells
49. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
50. The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.